For Providers

How can 24-chromosome PGS help my patients?

Preimplantation Genetic Screening (PGS) for chromosomal aneuploidies in conjunction with an In Vitro Fertilization (IVF) cycle will improve your patient's chances of a healthy and successful transfer, and subsequent pregnancy, by:

Nearly half of all in-vitro embryos have chromosomal abnormalities.1 All couples are at risk for aneuploidy, regardless of pregnancy history. Moreover, aneuploidy rates increase with maternal age from approximately 30% at age 35, to 85% at age 42.

24-chromosome PGS is performed on Day 5/6 blastocyst biopsies, with embryo cryopreservation, and a future frozen embryo transfer (FET). Biopsied samples are analyzed in RGI's CAP, CLIA and NY State certified laboratory. Results can be expected within 7-10 business days.

Patients with any of the following indications may benefit from RGI's 24-chromosome PGS: